Novartis completes acquisition of Tourmaline Bio, deepens cardiovascular innovation.

Novartis has completed its acquisition of Tourmaline Bio, making Tourmaline an indirect wholly owned subsidiary. The acquisition aligns with Novartis' strategy to deepen expertise in cardiovascular innovation, particularly in areas related to residual inflammation in atherosclerotic cardiovascular disease. Novartis plans to collaborate with Tourmaline's team to advance the promising asset Pacibekitug, which targets anti-IL-6 mechanisms.